Tenosynovial giant cell tumor

Area of Science:

• Orthopedics
• Pathology
• Oncology

Background:

• Tenosynovial Giant Cell Tumor (TGCT) comprises benign neoplastic lesions originating from the synovium.
• TGCT presents in localized and diffuse forms, impacting joints, bursae, and tendon sheaths.
• The pathogenesis involves stromal cell mutations leading to colony-stimulating factor 1 (CSF1) overexpression and recruitment of CSF1R-expressing cells.

Purpose of the Study:

• To provide a comprehensive overview of Tenosynovial Giant Cell Tumor (TGCT).
• To detail the etiology, cellular composition, diagnostic modalities, and treatment strategies for TGCT.
• To highlight the role of CSF1 in TGCT development.

Main Methods:

• Review of existing literature on TGCT.
• Analysis of histological features and imaging characteristics.
• Summary of current treatment approaches including surgery, radiotherapy, and chemotherapy.

Main Results:

• TGCT lesions are characterized by a mix of histiocyte-like cells, synovial cells, multinucleated giant cells, and mononuclear phagocytes.
• Hemosiderin deposition is a key feature, best visualized on MRI.
• Histological examination remains the definitive diagnostic method.

Conclusions:

• TGCT requires accurate diagnosis through histology and MRI for effective management.
• Surgical resection is the primary treatment, with radiotherapy and chemotherapy as alternative options.
• Understanding the molecular basis, particularly CSF1 signaling, is key to managing TGCT.